Pompa-Mera Ericka N, Arroyo-Matus Pablo, Ocaña-Mondragón Alicia, González-Bonilla César R, Yépez-Mulia Lilián
Unidad de Investigación en Enfermedades Infecciosas y Parasitarias, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, IMSS, Mexico City, Mexico; Unidad de Investigación Médica en Inmunología e Infectología, Hospital de Infectología, Centro Médico Nacional La Raza, IMSS, Mexico City, Mexico; Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Unidad de Investigación en Enfermedades Infecciosas y Parasitarias, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, IMSS, Mexico City, Mexico.
Res Vet Sci. 2014 Dec;97(3):533-45. doi: 10.1016/j.rvsc.2014.09.010. Epub 2014 Sep 28.
The development of a veterinary vaccine against T. spiralis infection is an alternative strategy to control trichinellosis. In an effort to develop an efficient vaccine, BALB/c mice were immunized with attenuated Salmonella enterica serovar Typhimurium SL3261 that expresses a 30-mer peptide (Ag30) derived from the gp43 of T. spiralis muscle larvae fused to three copies of the molecular adjuvant P28 (Ag30-P283) and it was either displayed on the surface or secreted by recombinant Salmonella strains. Salmonella strain secreting Ag30-P283, reduced the adult worm burden 92.8% following challenge with T. spiralis muscle larvae compared to 42% achieved by recombinant Salmonella displaying Ag30-P283 on the surface. The protection induced by secreted Ag30-P283 was associated with a mixed Th1/Th2 with predominance of Th2 phenotype, which was characterized by the production of IgG1, intestinal IgA antibodies and IL-5 secretion. This finding could provide an efficient platform technology for the design of novel vaccination strategies.
开发针对旋毛虫感染的兽用疫苗是控制旋毛虫病的一种替代策略。为了开发一种高效疫苗,用表达源自旋毛虫肌幼虫gp43的30肽(Ag30)并与三个分子佐剂P28拷贝融合(Ag30-P283)的减毒肠炎沙门氏菌血清型鼠伤寒沙门氏菌SL3261免疫BALB/c小鼠,该抗原要么展示在表面,要么由重组沙门氏菌菌株分泌。与表面展示Ag30-P283的重组沙门氏菌相比,分泌Ag30-P283的沙门氏菌菌株在用旋毛虫肌幼虫攻击后,成虫负荷降低了92.8%,而表面展示Ag30-P283的重组沙门氏菌降低了42%。分泌的Ag30-P283诱导的保护作用与以Th2表型为主的Th1/Th2混合反应有关,其特征是产生IgG1、肠道IgA抗体和分泌IL-5。这一发现可为新型疫苗接种策略的设计提供一个高效的平台技术。